In the course of the process development of Retigabine, two possible potential impurities were observed by simple reverse phase high-performance liquid chromatography (HPLC). Primarily, the two impurities were identified by the liquid chromatography–mass spectrometry (LC–MS) data followed by synthesized and Characterized these two impurities as dimers of Retigabine. Based on the spectral data (1H NMR, 13CNMR, IR and MS), the structure of Impurity-1 and Impurity-2 were characterized as diethyl (4,4'- diamino-6,6'-bis((4-fluorobenzyl)amino)-[1,1'-biphenyl]-3,3'-diyl)dicarbamate and diethyl (methylenebis(6-amino-4-((4-fluorobenzyl)amino)-3,1-phenylene))dicarbamate.